MX347322B - Ratones que expresan una cadena ligera con regiones constantes de raton y variables lambda humanas. - Google Patents

Ratones que expresan una cadena ligera con regiones constantes de raton y variables lambda humanas.

Info

Publication number
MX347322B
MX347322B MX2015009162A MX2015009162A MX347322B MX 347322 B MX347322 B MX 347322B MX 2015009162 A MX2015009162 A MX 2015009162A MX 2015009162 A MX2015009162 A MX 2015009162A MX 347322 B MX347322 B MX 347322B
Authority
MX
Mexico
Prior art keywords
sequences
mice
express
mouse constant
constant regions
Prior art date
Application number
MX2015009162A
Other languages
English (en)
Inventor
J Murphy Andrew
Macdonald Lynn
Gurer Cagan
Stevens Sean
A Hosiawa Karolina
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX347322B publication Critical patent/MX347322B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/02—Animal zootechnically ameliorated
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0381—Animal model for diseases of the hematopoietic system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Environmental Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Position Input By Displaying (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)

Abstract

La presente invención se refiere a ratones modificados genéticamente que expresan secuencias variables .? humanas (hV?.), lo que incluye ratones que expresan secuencias hV? de un locus endógeno de la cadena ligera ? de ratón, ratones que expresan secuencias hV?. de un locus endógeno de la cadena ligera ? de ratón, y ratones que expresan secuencias hV? a partir de un transgene o un episoma en los que la secuencia hV?. está unida a una secuencia constante de ratón. Se proporcionan ratones que son una fuente de secuencias variables ?. humanas mutadas somáticamente útiles para producir proteínas de unión a antígenos. Se proporcionan composiciones y métodos para producir proteínas de unión a antígenos que comprenden secuencias variables ?. humanas, que incluyen anticuerpos humanos.
MX2015009162A 2010-06-22 2011-06-22 Ratones que expresan una cadena ligera con regiones constantes de raton y variables lambda humanas. MX347322B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35731410P 2010-06-22 2010-06-22
US35731710P 2010-06-22 2010-06-22
PCT/US2011/041366 WO2011163311A1 (en) 2010-06-22 2011-06-22 Mice expressing alight chain with human lambda variable and mouse constant regions

Publications (1)

Publication Number Publication Date
MX347322B true MX347322B (es) 2017-04-21

Family

ID=44509861

Family Applications (6)

Application Number Title Priority Date Filing Date
MX2015009162A MX347322B (es) 2010-06-22 2011-06-22 Ratones que expresan una cadena ligera con regiones constantes de raton y variables lambda humanas.
MX2012015300A MX336344B (es) 2010-06-22 2011-06-22 Ratones que expresan una cadena ligera con regiones constantes de raton y variables lambda humanas.
MX2015008807A MX348942B (es) 2010-06-22 2011-06-22 Ratones que expresan una cadena ligera hibrida de inmunoglobulina.
MX2012015298A MX2012015298A (es) 2010-06-22 2011-06-22 Ratones con cadena ligera hibrida.
MX2015008806A MX347318B (es) 2010-06-22 2011-06-22 Ratones que expresan una cadena ligera hibrida de inmunoglobulina.
MX2022002117A MX2022002117A (es) 2010-06-22 2012-12-19 Ratones que expresan una cadena ligera hibrida de inmunoglobulina.

Family Applications After (5)

Application Number Title Priority Date Filing Date
MX2012015300A MX336344B (es) 2010-06-22 2011-06-22 Ratones que expresan una cadena ligera con regiones constantes de raton y variables lambda humanas.
MX2015008807A MX348942B (es) 2010-06-22 2011-06-22 Ratones que expresan una cadena ligera hibrida de inmunoglobulina.
MX2012015298A MX2012015298A (es) 2010-06-22 2011-06-22 Ratones con cadena ligera hibrida.
MX2015008806A MX347318B (es) 2010-06-22 2011-06-22 Ratones que expresan una cadena ligera hibrida de inmunoglobulina.
MX2022002117A MX2022002117A (es) 2010-06-22 2012-12-19 Ratones que expresan una cadena ligera hibrida de inmunoglobulina.

Country Status (30)

Country Link
US (22) US9035128B2 (es)
EP (7) EP2568049B1 (es)
JP (16) JP6009441B2 (es)
KR (16) KR101970944B1 (es)
CN (4) CN103068994B (es)
AU (1) AU2011271046B2 (es)
BR (3) BR112012033248A2 (es)
CA (2) CA2804311C (es)
CY (5) CY1117537T1 (es)
DK (5) DK2905338T3 (es)
ES (5) ES2576928T3 (es)
HR (5) HRP20160497T1 (es)
HU (5) HUE044001T2 (es)
IL (12) IL300712B2 (es)
LT (4) LT3034608T (es)
ME (5) ME02444B (es)
MX (6) MX347322B (es)
MY (6) MY195217A (es)
NO (1) NO2905338T3 (es)
NZ (6) NZ627119A (es)
PL (5) PL2568049T3 (es)
PT (5) PT2480676E (es)
RS (5) RS54891B1 (es)
RU (3) RU2590594C2 (es)
SG (4) SG186391A1 (es)
SI (5) SI3034608T1 (es)
SM (5) SMT201700506T1 (es)
TR (1) TR201905992T4 (es)
WO (2) WO2011163314A1 (es)
ZA (5) ZA201300063B (es)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
WO2010039900A2 (en) 2008-09-30 2010-04-08 Aliva Biopharmaceuticals, Inc. Non-human mammals for the production of chimeric antibodies
KR101711222B1 (ko) 2008-12-18 2017-02-28 에라스무스 유니버시티 메디컬 센터 로테르담 인간화 항체들을 발현하는 비-인간 유전자이식 동물들 및 그의 이용
US9445581B2 (en) * 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
ES2948572T3 (es) 2009-07-08 2023-09-14 Kymab Ltd Modelos de roedores y moléculas terapéuticas
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
ES2547142T5 (es) 2010-02-08 2021-12-09 Regeneron Pharma Cadena ligera común de ratón
KR20210010942A (ko) 2010-03-31 2021-01-28 아블렉시스, 엘엘씨 키메라 항체의 제조를 위한 비-인간 동물의 유전적 조작
MY195217A (en) * 2010-06-22 2023-01-11 Regeneron Pharma MICE Expressing An Immunoglobulin Hybrid Light Chain
US10662256B2 (en) 2010-07-26 2020-05-26 Trianni, Inc. Transgenic mammals and methods of use thereof
EP2597945B1 (en) 2010-07-26 2020-07-22 Trianni, Inc. Transgenic animals and methods of use
US10793829B2 (en) 2010-07-26 2020-10-06 Trianni, Inc. Transgenic mammals and methods of use thereof
IL315833A (en) * 2010-08-02 2024-11-01 Regeneron Pharma Mice producing binding proteins containing VL regions
IL273982B2 (en) 2011-08-05 2023-03-01 Regeneron Pharma Humanized mice possess a universal light chain
WO2013041845A2 (en) 2011-09-19 2013-03-28 Kymab Limited Animals, repertoires & methods
EP2757875B2 (en) 2011-09-19 2023-03-22 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
US9253965B2 (en) * 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
SG11201403326VA (en) * 2011-12-20 2014-07-30 Regeneron Pharma Humanized light chain mice
RU2664473C2 (ru) 2012-03-16 2018-08-17 Регенерон Фармасьютикалз, Инк. ОТЛИЧНЫЕ ОТ ЧЕЛОВЕКА ЖИВОТНЫЕ, ЭКСПРЕССИРУЮЩИЕ ЧУВСТВИТЕЛЬНЫЕ К pН ПОСЛЕДОВАТЕЛЬНОСТИ ИММУНОГЛОБУЛИНОВ
EP2825036B1 (en) 2012-03-16 2018-05-02 Regeneron Pharmaceuticals, Inc. Histidine engineered light chain antibodies and genetically modified rodents for generating the same
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
AU2013204581B2 (en) 2012-03-16 2015-06-25 Regeneron Pharmaceuticals, Inc. Non-human animals expressing pH-sensitive immunoglobulin sequences
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
WO2013144567A1 (en) 2012-03-28 2013-10-03 Kymab Limited Transgenic non-human vertebrate for the expression of class - switched, fully human, antibodies
SMT201800435T1 (it) 2013-02-20 2018-09-13 Regeneron Pharma Animali non umani con sequenze della catena pesante dell’immunoglobulina modificate riferimento incrociato a domande correlate
AU2014244020B2 (en) * 2013-03-13 2020-06-04 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
EP3841876A1 (en) 2013-03-14 2021-06-30 Erasmus University Medical Center Rotterdam Transgenic mouse for antibody production
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
RU2019121863A (ru) * 2013-09-18 2019-08-29 Регенерон Фармасьютикалз, Инк. Антитела со встроенным в легкие цепи гистидином и генетически модифицированные отличные от человека животные для их получения
ES2993142T3 (en) 2013-10-01 2024-12-23 Kymab Ltd Animal models and therapeutic molecules
EP3092007A4 (en) * 2014-01-10 2017-06-07 Allermabs Co. Ltd. Transgenic animals capable of producing humanized ige at much higher levels than mouse ige
BR112016021572A2 (pt) 2014-03-21 2017-10-03 Regeneron Pharma Métodos para preparar um animal não humano geneticamente modificado e para produzir proteínas de ligação, hibridoma, ácido nucleico, célula, e, proteína de ligação
ES2762640T3 (es) 2014-03-21 2020-05-25 Regeneron Pharma Proteínas VL de unión a antígeno que exhiben diferentes características de unión
AU2015271709B2 (en) 2014-06-06 2020-11-26 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
RU2017113134A (ru) 2014-09-19 2018-10-19 Регенерон Фармасьютикалз, Инк. Химерные антигенные рецепторы
SG11201702606TA (en) 2014-10-03 2017-04-27 Massachusetts Inst Technology Antibodies that bind ebola glycoprotein and uses thereof
TWI711630B (zh) 2014-11-21 2020-12-01 美商必治妥美雅史谷比公司 抗ｃｄ７３抗體及其用途
PT3233912T (pt) 2014-12-19 2021-08-09 Regenesance B V Antocorpos que se ligam a c6 humano e utilizações destes
JP6180663B2 (ja) 2014-12-23 2017-08-16 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｔｉｇｉｔに対する抗体
WO2016124709A1 (de) 2015-02-05 2016-08-11 Basf Se Solarkraftwerk mit einem ersten wärmeträgerkreislauf und einem zweiten wärmeträgerkreislauf
EP3271403A1 (en) * 2015-03-19 2018-01-24 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
MX2017015041A (es) 2015-05-29 2018-02-26 Squibb Bristol Myers Co Anticuerpos contra el miembro 4 de la superfamilia del receptor del factor de necrosis tumoral (ox40) y sus usos.
MX2017016502A (es) 2015-06-29 2018-03-12 Univ Rockefeller Anticuerpos contra cd40 con actividad agonista mejorada.
CN105274116B (zh) * 2015-10-21 2020-09-29 重庆金迈博生物科技有限公司 一种制备人源化抗体的核酸分子及其应用
JP6983776B2 (ja) 2015-11-19 2021-12-17 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company グルココルチコイド誘発腫瘍壊死因子受容体（ｇｉｔｒ）に対する抗体およびその使用
EP3384030A4 (en) 2015-12-03 2019-07-03 Trianni, Inc. IMPROVED IMMUNOGLULINIVITY
WO2017136734A1 (en) 2016-02-04 2017-08-10 Trianni, Inc. Enhanced production of immunoglobulins
EP4406550A3 (en) 2016-03-04 2024-10-16 The Rockefeller University Antibodies to cd40 with enhanced agonist activity
CA3016187A1 (en) 2016-03-04 2017-09-08 Bristol-Myers Squibb Company Combination therapy with anti-cd73 antibodies
US10968279B2 (en) 2016-05-09 2021-04-06 Bristol-Myers Squibb Company TL1A antibodies and uses thereof
MX2018014172A (es) 2016-05-20 2019-08-22 Regeneron Pharma Métodos para romper la tolerancia inmunológica usando múltiples arn guías.
CN109640644B (zh) 2016-06-03 2021-10-26 瑞泽恩制药公司 表达外源末端脱氧核苷酸转移酶的非人动物
WO2017214089A1 (en) * 2016-06-06 2017-12-14 Regeneron Pharmaceuticals, Inc. Non-human animals expressing antibodies with human lambda light chains
US20170371963A1 (en) * 2016-06-27 2017-12-28 Facebook, Inc. Systems and methods for identifying matching content
EP4512829A3 (en) 2016-07-14 2025-06-11 Bristol-Myers Squibb Company Antibodies against tim3 and uses thereof
WO2018044970A1 (en) 2016-08-31 2018-03-08 University Of Rochester Human monoclonal antibodies to human endogenous retrovirus k envelope (herv-k) and uses thereof
CR20210094A (es) 2016-10-13 2021-03-31 Massachusetts Inst Technology ANTICUERPOS QUE SE UNEN A LA PROTEÍNA DE ENVOLTURA DEL VIRUS ZIKA Y USOS DE LOS MISMOS (Divisional 2019-0193)
CN109906272A (zh) 2016-10-31 2019-06-18 国立大学法人鸟取大学 产生人抗体的非人动物和使用该非人动物的人抗体制作方法
CA3038720A1 (en) 2016-11-04 2018-07-12 Regeneron Pharmaceuticals, Inc. Non-human animals having an engineered immunoglobulin lambda light chain locus
EP3583124A1 (en) 2017-02-17 2019-12-25 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
SG11202003044SA (en) 2017-12-05 2020-04-29 Regeneron Pharma Non-human animals having an engineered immunoglobulin lambda light chain and uses thereof
CN120192415A (zh) 2018-01-12 2025-06-24 百时美施贵宝公司 抗tim3抗体及其用途
PE20210665A1 (es) 2018-03-23 2021-03-31 Bristol Myers Squibb Co Anticuerpos contra mica y/o micb y sus usos
US20210051929A1 (en) 2018-03-24 2021-02-25 Regeneron Pharmaceuticals, Inc. Genetically modified non-human animals for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof
CA3093850A1 (en) 2018-03-26 2019-10-03 Regeneron Pharmaceuticals, Inc. Humanized rodents for testing therapeutic agents
US11337409B2 (en) 2018-06-08 2022-05-24 Crystal Bioscience Inc. Transgenic animal for producing diversified antibodies that have the same light chain I
IL318469A (en) 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
WO2020085011A1 (ja) 2018-10-26 2020-04-30 ビークルエナジージャパン株式会社 電池制御装置
US11274150B2 (en) 2018-11-16 2022-03-15 Bristol-Myers Squibb Company Anti-human natural killer cell inhibitory receptor group 2A protein (NKG2A) antibodies
WO2020154293A1 (en) 2019-01-22 2020-07-30 Bristol-Myers Squibb Company Antibodies against il-7r alpha subunit and uses thereof
US11464217B2 (en) 2019-02-22 2022-10-11 Regeneron Pharmaceuticals, Inc. Rodents having genetically modified sodium channels and methods of use thereof
SG11202111258TA (en) * 2019-06-05 2021-11-29 Regeneron Pharma Non-human animals having a limited lambda light chain repertoire expressed from the kappa locus and uses thereof
EP3993623B1 (en) * 2019-07-01 2025-02-19 Trianni, Inc. Transgenic rodents and methods of use thereof
CN114901678A (zh) 2019-12-02 2022-08-12 瑞泽恩制药公司 肽-mhc ii蛋白构建体及其用途
US20230192867A1 (en) 2020-05-15 2023-06-22 Bristol-Myers Squibb Company Antibodies to garp
KR20230024822A (ko) * 2020-06-25 2023-02-21 주식회사 휴맵 이형접합성 형질전환 동물
TW202229328A (zh) 2020-09-11 2022-08-01 美商再生元醫藥公司 抗原特異性抗體之鑑定及產生
JP2024500399A (ja) 2020-12-16 2024-01-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化Ｆｃアルファ受容体を発現するマウス
IL303868A (en) 2020-12-23 2023-08-01 Regeneron Pharma Nucleic acids encoding anchor-modified antibodies and uses thereof
CA3197426A1 (en) 2020-12-23 2022-06-30 Regeneron Pharmaceuticals, Inc. Methods for obtaining antibodies that bind transmembrane proteins and cells that produce the same
WO2023199655A1 (ja) 2022-04-13 2023-10-19 日本精工株式会社 軸受装置の状態の検出方法、検出装置、およびプログラム
USD999969S1 (en) * 2022-04-29 2023-09-26 Shenzhen Intellirocks Tech. Co., Ltd. Lamp
WO2024163477A1 (en) 2023-01-31 2024-08-08 University Of Rochester Immune checkpoint blockade therapy for treating staphylococcus aureus infections
CN121079326A (zh) 2023-05-04 2025-12-05 诺瓦森塔股份有限公司 抗cd161抗体及其使用方法
WO2025184208A1 (en) 2024-02-27 2025-09-04 Bristol-Myers Squibb Company Anti-ceacam5 antibodies and uses thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US7041871B1 (en) * 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992018619A1 (en) 1991-04-10 1992-10-29 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
CA2078539C (en) * 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
US6632976B1 (en) 1995-08-29 2003-10-14 Kirin Beer Kabushiki Kaisha Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene
EP1500329B1 (en) * 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
US6774279B2 (en) 1997-05-30 2004-08-10 Carnegie Institution Of Washington Use of FLP recombinase in mice
GB9823930D0 (en) * 1998-11-03 1998-12-30 Babraham Inst Murine expression of human ig\ locus
CN101498731A (zh) * 2000-05-18 2009-08-05 日本烟草产业株式会社 抗协同刺激信号转导分子ailim的人单克隆抗体及其药物用途
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
ES2405944T3 (es) * 2000-11-30 2013-06-04 Medarex, Inc. Ácidos nucleicos que codifican las secuencias de inmunoglobulina humana reorganizadas a partir de ratones transcromoscómicos transgénicos zadas
GB0031284D0 (en) * 2000-12-21 2001-01-31 Ks Biomedix Ltd High affinity antibodies
EP1970448A1 (en) * 2001-05-11 2008-09-17 Kirin Pharma Kabushiki Kaisha Human artificial chromosome containting human antibody lambda light chain and non-human animal containting the human artificial chromosome capable of genetic transmission
GB0115256D0 (en) * 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
EP1461442B1 (en) 2001-11-30 2017-09-06 Amgen Fremont Inc. Transgenic animals bearing human ig lambda light chain genes
US20030217171A1 (en) 2002-05-17 2003-11-20 Von Stuermer Wolfgang R. Self-replicating and self-installing software apparatus
MXPA06000562A (es) * 2003-07-15 2006-03-30 Therapeutic Human Polyclonals Loci de inmunoglobulina humanizada.
CN1605628A (zh) * 2003-09-03 2005-04-13 中国疾病预防控制中心病毒病预防控制所 Cho细胞生产的人源抗甲肝病毒基因工程抗体
ME01803B (me) * 2004-08-05 2010-12-31 Genentech Inc Humanizovani anti-cmet antagonisti
PL2767161T3 (pl) 2004-10-19 2018-09-28 Regeneron Pharmaceuticals, Inc. Sposób wytwarzania zwierzęcia homozygotycznego pod względem modyfikacji genetycznej
JP4642862B2 (ja) * 2004-12-29 2011-03-02 ユーハン・コーポレイション ヒト腫瘍壊死因子−アルファに特異的なヒト化抗体
WO2007117410A2 (en) 2006-03-31 2007-10-18 Medarex, Inc. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
CN101501073A (zh) * 2006-08-22 2009-08-05 G2英弗勒美欣私人有限公司 抗体制备方法
CN101522716B (zh) 2006-10-02 2013-03-20 瑞泽恩制药公司 抗人il-4受体的高亲和力人抗体
US7864492B2 (en) 2006-10-31 2011-01-04 Siemens Industry, Inc. Systems and methods for arc fault detection
DE102007045897A1 (de) 2007-09-26 2009-04-09 Carl Zeiss Microimaging Gmbh Verfahren zur mikroskopischen dreidimensionalen Abbildung einer Probe
CA2721231C (en) * 2008-04-14 2015-10-06 Innovative Targeting Solutions Inc. Sequence diversity generation in immunoglobulins
EP2669298A3 (en) 2008-05-23 2014-02-26 Ablexis, LLC Single variable immunoglobulin domain comprising VL-DH-JL
WO2010039900A2 (en) * 2008-09-30 2010-04-08 Aliva Biopharmaceuticals, Inc. Non-human mammals for the production of chimeric antibodies
KR101711222B1 (ko) * 2008-12-18 2017-02-28 에라스무스 유니버시티 메디컬 센터 로테르담 인간화 항체들을 발현하는 비-인간 유전자이식 동물들 및 그의 이용
ES2948572T3 (es) * 2009-07-08 2023-09-14 Kymab Ltd Modelos de roedores y moléculas terapéuticas
ES2547142T5 (es) * 2010-02-08 2021-12-09 Regeneron Pharma Cadena ligera común de ratón
CA2802591A1 (en) 2010-06-17 2011-12-22 Kymab Limited Animal models and therapeutic molecules
MY195217A (en) * 2010-06-22 2023-01-11 Regeneron Pharma MICE Expressing An Immunoglobulin Hybrid Light Chain

Also Published As

Publication number Publication date
SMT201700506T1 (it) 2018-01-11
KR20210134424A (ko) 2021-11-09
ZA201300063B (en) 2014-09-25
KR20190049932A (ko) 2019-05-09
HUE036597T2 (hu) 2018-07-30
US9226484B2 (en) 2016-01-05
AU2011271043A1 (en) 2013-01-31
MX2012015300A (es) 2013-05-01
BR112012033248A2 (pt) 2017-11-28
MX336344B (es) 2016-01-15
KR101945352B1 (ko) 2019-02-07
HRP20171666T1 (hr) 2017-12-15
ES2646052T3 (es) 2017-12-11
HK1170766A1 (zh) 2013-03-08
RU2724736C2 (ru) 2020-06-25
DK2905338T3 (da) 2017-11-06
SMT201600213B (it) 2016-08-31
US20150246977A1 (en) 2015-09-03
US20150246976A1 (en) 2015-09-03
CN104404050B (zh) 2018-06-08
NZ605758A (en) 2014-08-29
KR20130121814A (ko) 2013-11-06
LT2568049T (lt) 2016-10-10
US9399683B2 (en) 2016-07-26
US9006511B2 (en) 2015-04-14
EP2480675B1 (en) 2016-04-06
ME02444B (me) 2016-09-20
IL282872A (en) 2021-06-30
CY1118126T1 (el) 2017-06-28
PT3034608T (pt) 2019-05-28
SMT201600229B (es) 2016-08-31
IL300712B1 (en) 2024-07-01
JP2017006152A (ja) 2017-01-12
ES2721749T3 (es) 2019-08-05
HK1168384A1 (zh) 2012-12-28
MY157477A (en) 2016-06-15
MY195214A (en) 2023-01-11
US9844212B2 (en) 2017-12-19
NZ707198A (en) 2016-04-29
KR101975884B1 (ko) 2019-05-10
LT3034608T (lt) 2019-05-27
CN104342455A (zh) 2015-02-11
IL291301B1 (en) 2023-03-01
JP2025027148A (ja) 2025-02-26
DK2480676T3 (en) 2016-06-20
US9394373B2 (en) 2016-07-19
JP2018201528A (ja) 2018-12-27
US9012717B2 (en) 2015-04-21
ZA201404600B (en) 2015-09-30
JP2013531501A (ja) 2013-08-08
US20150173332A1 (en) 2015-06-25
KR20230036157A (ko) 2023-03-14
US9850462B2 (en) 2017-12-26
SG186391A1 (en) 2013-01-30
KR102059909B1 (ko) 2019-12-27
US20130323790A1 (en) 2013-12-05
KR102193823B1 (ko) 2020-12-22
KR102506001B1 (ko) 2023-03-07
BR122020013427B1 (pt) 2021-08-03
KR20180135996A (ko) 2018-12-21
KR101991234B1 (ko) 2019-06-20
PL2568049T3 (pl) 2017-03-31
KR20200143511A (ko) 2020-12-23
RU2601297C2 (ru) 2016-10-27
US20140137275A1 (en) 2014-05-15
IL300712B2 (en) 2024-11-01
KR101934852B1 (ko) 2019-01-04
US20160057979A1 (en) 2016-03-03
CY1117692T1 (el) 2017-05-17
HRP20160497T1 (hr) 2016-07-15
JP2020062061A (ja) 2020-04-23
ZA201300062B (en) 2014-09-25
US9206261B2 (en) 2015-12-08
AU2011271046A1 (en) 2013-01-31
MX348942B (es) 2017-07-04
JP2016010417A (ja) 2016-01-21
LT2480675T (lt) 2016-10-10
KR102320944B1 (ko) 2021-11-04
SI3034608T1 (sl) 2019-06-28
US20150176002A1 (en) 2015-06-25
NZ627119A (en) 2015-05-29
EP2480675A1 (en) 2012-08-01
US20200239837A1 (en) 2020-07-30
JP7236409B2 (ja) 2023-03-09
SI2480675T1 (sl) 2016-08-31
PT2480675T (pt) 2016-07-11
CA2804311A1 (en) 2011-12-29
BR112012032991B1 (pt) 2021-08-10
CY1117537T1 (el) 2017-04-26
IL255179A0 (en) 2017-12-31
RU2013102596A (ru) 2014-07-27
IL291301A (en) 2022-05-01
KR20220150430A (ko) 2022-11-10
HUE044001T2 (hu) 2019-09-30
CN103068993A (zh) 2013-04-24
MX2012015298A (es) 2013-05-01
US9206263B2 (en) 2015-12-08
HRP20160794T1 (hr) 2016-08-12
JP2018201527A (ja) 2018-12-27
AU2011271046B2 (en) 2015-10-01
RS56589B1 (sr) 2018-02-28
CN104404050A (zh) 2015-03-11
KR102118565B1 (ko) 2020-06-03
US20150351371A1 (en) 2015-12-10
CA2803864C (en) 2017-05-16
ZA201506598B (en) 2017-03-29
RS54891B1 (sr) 2016-10-31
PL2480676T3 (pl) 2016-10-31
ME02440B (me) 2016-09-20
ME03386B (me) 2020-01-20
RU2016119423A3 (es) 2019-11-19
DK2480675T3 (en) 2016-08-01
BR112012032991A2 (pt) 2015-10-06
IL291301B2 (en) 2023-07-01
ES2576928T3 (es) 2016-07-12
JP6009441B2 (ja) 2016-10-19
CY1122877T1 (el) 2021-05-05
CN103068993B (zh) 2016-01-06
KR102266097B1 (ko) 2021-06-18
PT2905338T (pt) 2017-11-10
US9206262B2 (en) 2015-12-08
KR20130027555A (ko) 2013-03-15
IL247386A (en) 2017-07-31
KR101970944B1 (ko) 2019-04-23
KR20210073609A (ko) 2021-06-18
MY194456A (en) 2022-11-30
CY1119478T1 (el) 2018-03-07
SI2568049T1 (sl) 2016-10-28
US20240327785A1 (en) 2024-10-03
IL244450A (en) 2017-11-30
RS58736B1 (sr) 2019-06-28
US20150089680A1 (en) 2015-03-26
IL255179B (en) 2018-06-28
SG186390A1 (en) 2013-01-30
JP2013532974A (ja) 2013-08-22
EP3456832A1 (en) 2019-03-20
DK3034608T3 (da) 2019-05-06
JP6243384B2 (ja) 2017-12-06
WO2011163314A1 (en) 2011-12-29
EP2568049A1 (en) 2013-03-13
CA2803864A1 (en) 2011-12-29
KR20180135997A (ko) 2018-12-21
IL244450A0 (en) 2016-04-21
RU2013102595A (ru) 2014-07-27
AU2011271043A8 (en) 2016-01-21
EP2480676B1 (en) 2016-04-06
KR20190142436A (ko) 2019-12-26
ZA201404601B (en) 2016-02-24
US9540452B2 (en) 2017-01-10
SI2480676T1 (sl) 2016-10-28
MY195217A (en) 2023-01-11
HUE029692T2 (en) 2017-03-28
US20160060359A1 (en) 2016-03-03
KR102462042B1 (ko) 2022-11-03
US9334333B2 (en) 2016-05-10
SMT201900241T1 (it) 2019-05-10
IL300712A (en) 2023-04-01
US20120070861A1 (en) 2012-03-22
JP2021061863A (ja) 2021-04-22
EP2568049B1 (en) 2016-04-13
NZ707200A (en) 2016-04-29
US10266803B2 (en) 2019-04-23
US20180064078A1 (en) 2018-03-08
JP6073441B2 (ja) 2017-02-01
US9035128B2 (en) 2015-05-19
SG10201504324UA (en) 2015-07-30
IL269078B (en) 2021-05-31
IL282872B (en) 2022-04-01
IL259965B (en) 2019-02-28
US20150320023A1 (en) 2015-11-12
US20150173331A1 (en) 2015-06-25
NZ605751A (en) 2014-10-31
JP2019033765A (ja) 2019-03-07
HRP20190807T1 (hr) 2019-08-23
ME02442B (me) 2016-09-20
JP6963542B2 (ja) 2021-11-10
HRP20160865T1 (hr) 2016-10-07
HK1183321A1 (en) 2013-12-20
SG10201504568YA (en) 2015-07-30
PT2480676E (pt) 2016-06-09
KR102211911B1 (ko) 2021-02-05
CA2804311C (en) 2017-09-12
HUE030285T2 (en) 2017-05-29
KR102001430B1 (ko) 2019-07-18
HUE029691T2 (en) 2017-03-28
JP2017012204A (ja) 2017-01-19
JP2016010415A (ja) 2016-01-21
US9163092B2 (en) 2015-10-20
JP6341972B2 (ja) 2018-06-13
EP3034608A1 (en) 2016-06-22
RS55042B1 (sr) 2016-12-30
US9066502B2 (en) 2015-06-30
MY165287A (en) 2018-03-21
US20170107484A1 (en) 2017-04-20
RS55037B1 (sr) 2016-12-30
JP2020128440A (ja) 2020-08-27
MX2022002117A (es) 2022-03-17
HK1226766A1 (en) 2017-10-06
PL3034608T3 (pl) 2019-08-30
BR112012032991A8 (pt) 2020-09-29
IL259965A (en) 2018-07-31
KR20210013376A (ko) 2021-02-03
MY195212A (en) 2023-01-11
US20190203171A1 (en) 2019-07-04
RU2590594C2 (ru) 2016-07-10
US20130326647A1 (en) 2013-12-05
EP2905338A1 (en) 2015-08-12
CN104342455B (zh) 2017-05-31
IL313063A (en) 2024-07-01
JP6545773B2 (ja) 2019-07-17
CN103068994B (zh) 2016-01-20
SMT201600212B (it) 2016-08-31
MX347318B (es) 2017-04-21
EP3205726A1 (en) 2017-08-16
EP2905338B8 (en) 2018-01-24
CN103068994A (zh) 2013-04-24
NZ626979A (en) 2015-05-29
JP2023133554A (ja) 2023-09-22
PL2480675T3 (pl) 2017-03-31
PT2568049T (pt) 2016-07-11
AU2011271043A9 (en) 2015-10-01
KR20190014578A (ko) 2019-02-12
KR20200064166A (ko) 2020-06-05
US20120073004A1 (en) 2012-03-22
WO2011163311A1 (en) 2011-12-29
JP2022066449A (ja) 2022-04-28
SI2905338T1 (sl) 2017-12-29
US20190153384A1 (en) 2019-05-23
EP2905338B1 (en) 2017-08-02
ES2570131T3 (es) 2016-05-17
EP2480676A1 (en) 2012-08-01
PL2905338T3 (pl) 2018-01-31
TR201905992T4 (tr) 2019-05-21
IL223719A (en) 2016-10-31
US20170258059A1 (en) 2017-09-14
IL269078A (en) 2019-11-28
KR20190073584A (ko) 2019-06-26
JP2018023403A (ja) 2018-02-15
DK2568049T3 (en) 2016-08-01
EP3034608B1 (en) 2019-01-30
ME02902B (me) 2018-04-20
ES2575223T3 (es) 2016-06-27
IL264634B (en) 2019-09-26
AU2011271043B2 (en) 2015-10-01
NO2905338T3 (es) 2017-12-30
US9150662B2 (en) 2015-10-06
KR20190014576A (ko) 2019-02-12
RU2016119423A (ru) 2018-11-07
US9029628B2 (en) 2015-05-12
LT2905338T (lt) 2017-12-27
IL223720A (en) 2017-05-29
JP5988969B2 (ja) 2016-09-07

Similar Documents

Publication Publication Date Title
MX347322B (es) Ratones que expresan una cadena ligera con regiones constantes de raton y variables lambda humanas.
SG194466A1 (en) Non-human animals expressing antibodies having a common light chain
MX379533B (es) Ratones de cadena ligera universal humanizados.
IN2014DN08163A (es)
EP4545567A3 (en) Mice expressing a limited immunoglobulin light chain repertoire
MX2012009168A (es) Raton de cadena ligera comun.
NZ629639A (en) Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same
MX2015012540A (es) Ratón de cadena ligera común.
NZ717848A (en) Humanized non-human animals with restricted immunoglobulin heavy chain loci
MX2021000298A (es) Ratones con cadena ligera humanizada.
PH12013500933A1 (en) Methods and compositions for neural disease immunotherapy
HK1208994A1 (en) Methods for making fully human bispecific antibodies using a common light chain
TH146784A (th) หนูที่แสดงออกสายเบาไฮบริดของอิมมูโนโกลบูลิน